Immune Design (IMDZ) Misses Q4 EPS by 6c

Immune Design (NASDAQ: IMDZ) reported Q4 EPS of ($0.60), $0.06 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.06 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• Movano (MOVE) Misses Q2 EPS by 195c